These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

262 related articles for article (PubMed ID: 36168187)

  • 1. Asciminib vs bosutinib in CML patients pretreated with ≥2 tyrosine kinase inhibitors: Results from the Japanese subgroup analysis of ASCEMBL study.
    Yuda J; Doki N; Matsuoka H; Yokota T; Tomita A; Takahashi N; Matsumura I; Kubo K; Goto T; Kirito K; Maki A; Aoki M; Allepuz A; Minami Y
    Cancer Med; 2023 Feb; 12(3):2990-2998. PubMed ID: 36168187
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Asciminib in Patients With CML-CP Previously Treated With ≥ 2 Tyrosine Kinase Inhibitors: 96-Week Results From the Japanese Subgroup Analysis of the ASCEMBL Study.
    Minami Y; Doki N; Matsuoka H; Yokota T; Tomita A; Takahashi N; Kubo K; Goto T; Kirito K; Maki A; Aoki M; Dawson MK; Matsumura I
    Int J Hematol; 2024 Sep; 120(3):305-313. PubMed ID: 38888812
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Asciminib vs bosutinib in chronic-phase chronic myeloid leukemia previously treated with at least two tyrosine kinase inhibitors: longer-term follow-up of ASCEMBL.
    Hochhaus A; Réa D; Boquimpani C; Minami Y; Cortes JE; Hughes TP; Apperley JF; Lomaia E; Voloshin S; Turkina A; Kim DW; Abdo A; Fogliatto LM; le Coutre P; Sasaki K; Kim DDH; Saussele S; Annunziata M; Chaudhri N; Chee L; García-Gutiérrez V; Kapoor S; Allepuz A; Quenet S; Bédoucha V; Mauro MJ
    Leukemia; 2023 Mar; 37(3):617-626. PubMed ID: 36717654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs.
    Réa D; Mauro MJ; Boquimpani C; Minami Y; Lomaia E; Voloshin S; Turkina A; Kim DW; Apperley JF; Abdo A; Fogliatto LM; Kim DDH; le Coutre P; Saussele S; Annunziata M; Hughes TP; Chaudhri N; Sasaki K; Chee L; García-Gutiérrez V; Cortes JE; Aimone P; Allepuz A; Quenet S; Bédoucha V; Hochhaus A
    Blood; 2021 Nov; 138(21):2031-2041. PubMed ID: 34407542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Pharmacological and clinical profile of asciminib hydrochloride, a novel first-in-class tyrosine kinase inhibitor specifically targeting ABL myristoyl pocket].
    Chung J; Ariyoshi T; Yoneda T; Kagawa Y; Kawakita Y; Maki A
    Nihon Yakurigaku Zasshi; 2023; 158(3):273-281. PubMed ID: 37121712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Health care resource utilization in 3L + patients with chronic phase chronic myeloid leukemia receiving asciminib or bosutinib.
    Cortes JE; Rea D; Mauro MJ; Tran D; Wang P; Jadhav K; Yocolly A; Sasaki K
    J Med Econ; 2023; 26(1):915-923. PubMed ID: 37431294
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The EMA Assessment of Asciminib for the Treatment of Adult Patients With Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase Who Were Previously Treated With at Least Two Tyrosine Kinase Inhibitors.
    Tesileanu CMS; Michaleas S; Gonzalo Ruiz R; Mariz S; Fabriek BO; van Hennik PB; Dedorath J; Dekic B; Unkrig C; Brandt A; Koenig J; Enzmann H; Delgado J; Pignatti F
    Oncologist; 2023 Jul; 28(7):628-632. PubMed ID: 37141403
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Matching-adjusted indirect comparison of asciminib versus other treatments in chronic-phase chronic myeloid leukemia after failure of two prior tyrosine kinase inhibitors.
    Atallah E; Mauro MJ; Hochhaus A; Boquimpani C; Minami Y; Maheshwari VK; Saini L; Corbin R; Réa D
    J Cancer Res Clin Oncol; 2023 Aug; 149(9):6247-6262. PubMed ID: 36707445
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Asciminib (Scemblix): A third-line treatment option for chronic myeloid leukemia in chronic phase with or without T315I mutation.
    Monestime S; Al Sagheer T; Tadros M
    Am J Health Syst Pharm; 2023 Jan; 80(2):36-43. PubMed ID: 36197958
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure.
    Hughes TP; Mauro MJ; Cortes JE; Minami H; Rea D; DeAngelo DJ; Breccia M; Goh YT; Talpaz M; Hochhaus A; le Coutre P; Ottmann O; Heinrich MC; Steegmann JL; Deininger MWN; Janssen JJWM; Mahon FX; Minami Y; Yeung D; Ross DM; Tallman MS; Park JH; Druker BJ; Hynds D; Duan Y; Meille C; Hourcade-Potelleret F; Vanasse KG; Lang F; Kim DW
    N Engl J Med; 2019 Dec; 381(24):2315-2326. PubMed ID: 31826340
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exposure-Efficacy Analysis of Asciminib in Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase.
    Combes FP; Li YF; Hoch M; Lorenzo S; Ho YY; Sy SKB
    Clin Pharmacol Ther; 2022 Nov; 112(5):1040-1050. PubMed ID: 35776072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Asciminib in Newly Diagnosed Chronic Myeloid Leukemia.
    Hochhaus A; Wang J; Kim DW; Kim DDH; Mayer J; Goh YT; le Coutre P; Takahashi N; Kim I; Etienne G; Andorsky D; Issa GC; Larson RA; Bombaci F; Kapoor S; McCulloch T; Malek K; Yau L; Ifrah S; Hoch M; Cortes JE; Hughes TP;
    N Engl J Med; 2024 Sep; 391(10):885-898. PubMed ID: 38820078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Asciminib monotherapy in patients with chronic-phase chronic myeloid leukemia with the T315I mutation after ≥1 prior tyrosine kinase inhibitor: 2-year follow-up results.
    Cortes JE; Sasaki K; Kim DW; Hughes TP; Etienne G; Mauro MJ; Hochhaus A; Lang F; Heinrich MC; Breccia M; Deininger M; Goh YT; Janssen JJWM; Talpaz M; de Soria VGG; le Coutre P; DeAngelo DJ; Damon A; Cacciatore S; Polydoros F; Agrawal N; Rea D
    Leukemia; 2024 Jul; 38(7):1522-1533. PubMed ID: 38755421
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics of Asciminib in Tyrosine Kinase Inhibitor-Treated Patients with Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic and Acute Phases.
    Li YF; Combes FP; Hoch M; Lorenzo S; Sy SKB; Ho YY
    Clin Pharmacokinet; 2022 Oct; 61(10):1393-1403. PubMed ID: 35764773
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Health-related quality of life of patients with resistant/intolerant chronic phase chronic myeloid leukemia treated with asciminib or bosutinib in the phase 3 ASCEMBL trial.
    Réa D; Boquimpani C; Mauro MJ; Minami Y; Allepuz A; Maheshwari VK; D'Alessio D; Wu Y; Lawrance R; Narbutas S; Sharf G; Hochhaus A
    Leukemia; 2023 May; 37(5):1060-1067. PubMed ID: 37069326
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Real-World Evaluation of Treatment Patterns and Clinical Outcomes among Patients With Chronic Myeloid Leukemia in Chronic Phase Treated With Asciminib in Clinical Practice in the United States: Real-world asciminib treatment outcomes in CML-CP.
    Atallah EL; Wei D; Latremouille-Viau D; Rossi C; Damon A; Ferreira G; Guérin A; Jadhav K
    Clin Lymphoma Myeloma Leuk; 2024 Sep; ():. PubMed ID: 39426944
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The specificity of asciminib, a potential treatment for chronic myeloid leukemia, as a myristate-pocket binding ABL inhibitor and analysis of its interactions with mutant forms of BCR-ABL1 kinase.
    Manley PW; Barys L; Cowan-Jacob SW
    Leuk Res; 2020 Nov; 98():106458. PubMed ID: 33096322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Canadian real-world experience of asciminib treatment in heavily pre-treated chronic myeloid leukemia (CML) patients who failed multiple lines of tyrosine kinase inhibitor (TKI) therapy.
    Khadadah FM; Cerquozzi S; Olney HJ; Fraga C; Dudebout J; Xenocostas A; Finn N; Ethier V; Savoie ML; Busque L; Jamani K; Kuruvilla P; Faught C; Leber B; Kaedbey R; Assouline SE; Kim D
    Leuk Res; 2023 Oct; 133():107374. PubMed ID: 37657146
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDA Approval Summary: Asciminib for Ph+ CML in Chronic Phase Treated with Two or More Tyrosine Kinase Inhibitors and for the T315I Mutation.
    Pamuk GE; Chow ECY; Ionan AC; Chen H; Lee SL; Hsu V; Grimstein M; Zheng N; Sun J; Charlab R; Gehrke BJ; Vallejo J; Ehrlich LA; de Claro RA; Theoret MR
    Clin Cancer Res; 2024 Oct; 30(19):4266-4271. PubMed ID: 39088257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination of an aurora kinase inhibitor and the ABL tyrosine kinase inhibitor asciminib against ABL inhibitor-resistant CML cells.
    Okabe S; Moriyama M; Gotoh A
    Med Oncol; 2024 May; 41(6):142. PubMed ID: 38714583
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.